Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

医学 曲妥珠单抗 乳腺癌 肿瘤科 抗体-药物偶联物 曲妥珠单抗 内科学 转移性乳腺癌 化疗 癌症 抗体 单克隆抗体 免疫学
作者
Gϋnter von Minckwitz,Chiun‐Sheng Huang,Max S. Mano,Sibylle Loibl,Eleftherios P. Mamounas,Michael Untch,Norman Wolmark,Priya Rastogi,Andreas Schneeweiß,Andrés Redondo,Hans Holger Fischer,William Jacot,Alison Katherine Conlin,Claudia Arce-Salinas,Irene Wapnir,Christian Jackisch,Michael P. DiGiovanna,Peter Andreas Fasching,John Paul Crown,Pia Wülfing
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:380 (7): 617-628 被引量:2688
标识
DOI:10.1056/nejmoa1814017
摘要

BACKGROUND: Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit in patients with metastatic breast cancer that was previously treated with chemotherapy plus HER2-targeted therapy. METHODS: We conducted a phase 3, open-label trial involving patients with HER2-positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. Patients were randomly assigned to receive adjuvant T-DM1 or trastuzumab for 14 cycles. The primary end point was invasive disease-free survival (defined as freedom from ipsilateral invasive breast tumor recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral invasive breast cancer, distant recurrence, or death from any cause). RESULTS: At the interim analysis, among 1486 randomly assigned patients (743 in the T-DM1 group and 743 in the trastuzumab group), invasive disease or death had occurred in 91 patients in the T-DM1 group (12.2%) and 165 patients in the trastuzumab group (22.2%). The estimated percentage of patients who were free of invasive disease at 3 years was 88.3% in the T-DM1 group and 77.0% in the trastuzumab group. Invasive disease-free survival was significantly higher in the T-DM1 group than in the trastuzumab group (hazard ratio for invasive disease or death, 0.50; 95% confidence interval, 0.39 to 0.64; P<0.001). Distant recurrence as the first invasive-disease event occurred in 10.5% of patients in the T-DM1 group and 15.9% of those in the trastuzumab group. The safety data were consistent with the known safety profile of T-DM1, with more adverse events associated with T-DM1 than with trastuzumab alone. CONCLUSIONS: Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone. (Funded by F. Hoffmann-La Roche/Genentech; KATHERINE ClinicalTrials.gov number, NCT01772472 .).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
follower8107完成签到,获得积分10
刚刚
刚刚
1秒前
SunH发布了新的文献求助10
1秒前
2秒前
烧饼拌糖完成签到,获得积分10
2秒前
魔芋小心发布了新的文献求助10
2秒前
ldxghh发布了新的文献求助10
2秒前
一周八颗蛋完成签到,获得积分10
3秒前
3秒前
4秒前
国度发布了新的文献求助10
4秒前
梵羽发布了新的文献求助10
5秒前
suzy完成签到,获得积分10
5秒前
左白易发布了新的文献求助10
7秒前
8秒前
molihuakai的应助被jack采纳,获得10
8秒前
8秒前
今后的应助被wangxiaomin采纳,获得10
9秒前
俭朴灵竹发布了新的文献求助10
9秒前
9秒前
yuan完成签到,获得积分10
10秒前
10秒前
呆萌白薇完成签到,获得积分10
10秒前
盼盼发布了新的文献求助10
11秒前
水煮电吹风的应助被煎饼煎饼采纳,获得10
11秒前
11秒前
科研小白发布了新的文献求助10
13秒前
陌白一完成签到,获得积分10
13秒前
左白易完成签到,获得积分10
14秒前
跳跃的浩阑完成签到 ,获得积分10
16秒前
凶狠的洋葱完成签到,获得积分10
16秒前
dxtp01完成签到,获得积分10
17秒前
科研通AI6.3的应助被yuan采纳,获得10
17秒前
18秒前
田様的应助被盼盼采纳,获得10
18秒前
6682完成签到,获得积分10
19秒前
20秒前
Lucas的应助被十七采纳,获得10
20秒前
烂漫的烙完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571537
关于积分的说明 21818552
捐赠科研通 7778091
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479621